Advocates call for drug crisis to be declared public health emergency - Global News

In a follow-up on the measles outbreak in Sweden, no new cases of measles linked to the Urkult festival in Västernorrland have been reported in Sweden since the last update on September 9. The outbreak has been declared over as of October 14. A total of 40 cases were reported in the outbreak. In 28 cases, the spread of infection occurred during the Urkult festival. 12 people are considered to have been infected after contact with a person who was infected at the festival. The majority of the cases are school-age children and young adults. Most of the cases have been unvaccinated against measles. The cases have been reported from ten regions: Gotland (4 cases), Jämtland Härjedalen (6 cases), Skåne (2 cases), Stockholm (12 cases), Sörmland (3 cases), Uppsala (1 case), Värmland (2 cases), Västerbotten (7 cases), Västernorrland (2 cases) and Västra Götaland (1 case). One case has been reported from Finland. The regions’ infection tracing of the outbreak cases showed that the source of the outbreak was infected abroad.

Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.